Manji, Husseini K.
Johnson & Johnson (United States)
52 papers on CoChatORCID 0009-0007-1679-8749
Most cited papers
- Verified
Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study
Wajs, E., Leah, A., Morrison, R., Daly, E., Lane, R., Lim, P., Holder, R., Sanacora, G., Young, A. H., Kasper, S., et al. (2019) · European Neuropsychopharmacology
Treatment of Major DepressionElectroconvulsive Therapy Studies
Cited by 19
- Verified
S114. Efficacy and Safety of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Foster, K., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2018) · Biological Psychiatry
Treatment of Major DepressionElectroconvulsive Therapy Studies
Cited by 17
- Verified
Comment on a Word to the Wise About Intranasal Esketamine
Drevets, W. C., Singh, J. B., Hough, D., Daly, E. J., Popova, V., & Manji, H. (2019) · American Journal of Psychiatry
Treatment of Major DepressionElectroconvulsive Therapy Studies
Cited by 12
- Verified
Randomized, double-blind study of flexibly-dosed intranasal esketamine plus oral antidepressant vs. active control in treatment-resistant depression
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · European Neuropsychopharmacology
Treatment of Major DepressionElectroconvulsive Therapy Studies
Cited by 2
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free